

## Hepatocellular Carcinoma - Pipeline Review, H2 2017

URL:	<a href="https://marketpublishers.com/r/HDDA6A0D3B4EN.html">https://marketpublishers.com/r/HDDA6A0D3B4EN.html</a>
Date:	November 30, 2017
Pages:	1120
Price:	US\$ 2,500.00
ID:	HDDA6A0D3B4EN

### Hepatocellular Carcinoma - Pipeline Review, H2 2017

#### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatocellular Carcinoma - Pipeline Review, H2 2017, provides an overview of the Hepatocellular Carcinoma (Oncology) pipeline landscape.

Hepatocellular carcinoma (HCC) is a type of cancer originates from a liver cell (hepatocyte) which becomes cancerous. This type of cancer occurs more often in men than women. Symptoms include abdominal pain or tenderness, especially in the upper-right part, easy bruising or bleeding, enlarged abdomen and yellow skin or eyes (jaundice). The predisposing factors include alcohol abuse, autoimmune diseases of the liver, hepatitis B or C virus infection, inflammation of the liver that is long-term (chronic) and iron overload in the body (hemochromatosis). Treatment includes surgery, chemotherapy and radiation therapy.

#### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatocellular Carcinoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hepatocellular Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatocellular Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hepatocellular Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 12, 79, 51, 3, 72, 10 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 11, 7, 1, 26 and 2 molecules, respectively.

Hepatocellular Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatocellular Carcinoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Hepatocellular Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hepatocellular Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hepatocellular Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hepatocellular Carcinoma (Oncology)

## REASONS TO BUY

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hepatocellular Carcinoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hepatocellular Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Table of Content

Introduction

Hepatocellular Carcinoma - Overview

Hepatocellular Carcinoma - Therapeutics Development

Hepatocellular Carcinoma - Therapeutics Assessment

Hepatocellular Carcinoma - Companies Involved in Therapeutics Development

Hepatocellular Carcinoma - Drug Profiles

Hepatocellular Carcinoma - Dormant Projects 1068

Hepatocellular Carcinoma - Discontinued Products 1076

Hepatocellular Carcinoma - Product Development Milestones 1079

Appendix 1092

## LIST OF TABLES

Number of Products under Development for Hepatocellular Carcinoma, H2 2017  
Number of Products under Development by Companies, H2 2017  
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017  
Number of Products under Development by Companies, H2 2017 (Contd.2), H2 2017  
Number of Products under Development by Companies, H2 2017 (Contd.3), H2 2017  
Number of Products under Development by Companies, H2 2017 (Contd.4), H2 2017  
Number of Products under Development by Companies, H2 2017 (Contd.5), H2 2017  
Number of Products under Development by Companies, H2 2017 (Contd.6), H2 2017  
Number of Products under Development by Companies, H2 2017 (Contd.7), H2 2017  
Number of Products under Development by Companies, H2 2017 (Contd.8), H2 2017  
Number of Products under Development by Universities/Institutes, H2 2017  
Number of Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017  
Number of Products under Development by Universities/Institutes, H2 2017 (Contd.2), H2 2017  
Products under Development by Companies, H2 2017  
Products under Development by Companies, H2 2017 (Contd.1), H2 2017  
Products under Development by Companies, H2 2017 (Contd.2), H2 2017  
Products under Development by Companies, H2 2017 (Contd.3), H2 2017  
Products under Development by Companies, H2 2017 (Contd.4), H2 2017  
Products under Development by Companies, H2 2017 (Contd.5), H2 2017  
Products under Development by Companies, H2 2017 (Contd.6), H2 2017  
Products under Development by Companies, H2 2017 (Contd.7), H2 2017  
Products under Development by Companies, H2 2017 (Contd.8), H2 2017  
Products under Development by Companies, H2 2017 (Contd.9), H2 2017  
Products under Development by Companies, H2 2017 (Contd.10), H2 2017  
Products under Development by Companies, H2 2017 (Contd.11), H2 2017  
Products under Development by Companies, H2 2017 (Contd.12), H2 2017  
Products under Development by Companies, H2 2017 (Contd.13), H2 2017  
Products under Development by Universities/Institutes, H2 2017  
Products under Development by Universities/Institutes, H2 2017 (Contd.1), H2 2017  
Products under Development by Universities/Institutes, H2 2017 (Contd.2), H2 2017  
Number of Products by Stage and Target, H2 2017  
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017  
Number of Products by Stage and Target, H2 2017 (Contd.2), H2 2017  
Number of Products by Stage and Target, H2 2017 (Contd.3), H2 2017  
Number of Products by Stage and Target, H2 2017 (Contd.4), H2 2017  
Number of Products by Stage and Target, H2 2017 (Contd.5), H2 2017  
Number of Products by Stage and Target, H2 2017 (Contd.6), H2 2017  
Number of Products by Stage and Target, H2 2017 (Contd.7), H2 2017  
Number of Products by Stage and Mechanism of Action, H2 2017  
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017  
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.2), H2 2017  
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.3), H2 2017  
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.4), H2 2017  
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.5), H2 2017  
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.6), H2 2017  
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.7), H2 2017  
Number of Products by Stage and Route of Administration, H2 2017  
Number of Products by Stage and Molecule Type, H2 2017  
Hepatocellular Carcinoma - Pipeline by AbbVie Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Abivax SA, H2 2017  
Hepatocellular Carcinoma - Pipeline by ACEA Biosciences Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Advenchen Laboratories LLC, H2 2017  
Hepatocellular Carcinoma - Pipeline by Amgen Inc, H2 2017

Hepatocellular Carcinoma - Pipeline by AndroScience Corp, H2 2017  
Hepatocellular Carcinoma - Pipeline by ArQule Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Array BioPharma Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2017  
Hepatocellular Carcinoma - Pipeline by AstraZeneca Plc, H2 2017  
Hepatocellular Carcinoma - Pipeline by AVEO Pharmaceuticals Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Bayer AG, H2 2017  
Hepatocellular Carcinoma - Pipeline by BeiGene Ltd, H2 2017  
Hepatocellular Carcinoma - Pipeline by Bio-Cancer Treatment International Ltd, H2 2017  
Hepatocellular Carcinoma - Pipeline by Biomics Biotechnologies Co Ltd, H2 2017  
Hepatocellular Carcinoma - Pipeline by Bioneer Corp, H2 2017  
Hepatocellular Carcinoma - Pipeline by Blueprint Medicines Corp, H2 2017  
Hepatocellular Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H2 2017  
Hepatocellular Carcinoma - Pipeline by Boston Biomedical Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Bristol-Myers Squibb Co, H2 2017  
Hepatocellular Carcinoma - Pipeline by Can-Fite BioPharma Ltd, H2 2017  
Hepatocellular Carcinoma - Pipeline by CASI Pharmaceuticals Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by CBT Pharmaceuticals Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by CCRP Therapeutics GmbH, H2 2017  
Hepatocellular Carcinoma - Pipeline by Celgene Corp, H2 2017  
Hepatocellular Carcinoma - Pipeline by Celldex Therapeutics Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Cellivry Therapeutics Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Celsion Corp, H2 2017  
Hepatocellular Carcinoma - Pipeline by China Medical System Holdings Ltd, H2 2017  
Hepatocellular Carcinoma - Pipeline by Chipscreen Biosciences Ltd, H2 2017  
Hepatocellular Carcinoma - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017  
Hepatocellular Carcinoma - Pipeline by Conatus Pharmaceuticals Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Curevac AG, H2 2017  
Hepatocellular Carcinoma - Pipeline by Delcath Systems Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Double Bond Pharmaceutical International AB, H2 2017  
Hepatocellular Carcinoma - Pipeline by eFFECTOR Therapeutics Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Eiger BioPharmaceuticals Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Eisai Co Ltd, H2 2017  
Hepatocellular Carcinoma - Pipeline by Eli Lilly and Co, H2 2017  
Hepatocellular Carcinoma - Pipeline by Epeius Biotechnologies Corp, H2 2017  
Hepatocellular Carcinoma - Pipeline by Epizyme Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by eTheRNA Immunotherapies NV, H2 2017  
Hepatocellular Carcinoma - Pipeline by Eureka Therapeutics Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Exelixis Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017  
Hepatocellular Carcinoma - Pipeline by Faron Pharmaceuticals Oy, H2 2017  
Hepatocellular Carcinoma - Pipeline by Galaxy Biotech LLC, H2 2017  
Hepatocellular Carcinoma - Pipeline by Genelux Corp, H2 2017  
Hepatocellular Carcinoma - Pipeline by Genentech Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Genoscience Pharma, H2 2017  
Hepatocellular Carcinoma - Pipeline by Genosco Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Gilead Sciences Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by GlaxoSmithKline Plc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Golden Biotechnology Corp, H2 2017  
Hepatocellular Carcinoma - Pipeline by Green Cross Cell Corp, H2 2017  
Hepatocellular Carcinoma - Pipeline by Green Cross Corp, H2 2017  
Hepatocellular Carcinoma - Pipeline by H3 Biomedicine Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Horizon Pharma Plc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Immatics Biotechnologies GmbH, H2 2017  
Hepatocellular Carcinoma - Pipeline by Immunicum AB, H2 2017

Hepatocellular Carcinoma - Pipeline by Immunitor Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Immunomedics Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Immunovative Therapies Ltd, H2 2017  
Hepatocellular Carcinoma - Pipeline by In-Cell-Art SAS, H2 2017  
Hepatocellular Carcinoma - Pipeline by Incyte Corp, H2 2017  
Hepatocellular Carcinoma - Pipeline by Inovio Pharmaceuticals Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Inspyr Therapeutics Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by InteRNA Technologies BV, H2 2017  
Hepatocellular Carcinoma - Pipeline by Ipsen SA, H2 2017  
Hepatocellular Carcinoma - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017  
Hepatocellular Carcinoma - Pipeline by Johnson & Johnson, H2 2017  
Hepatocellular Carcinoma - Pipeline by KAHR medical Ltd, H2 2017  
Hepatocellular Carcinoma - Pipeline by Karcinolys SAS, H2 2017  
Hepatocellular Carcinoma - Pipeline by Kite Pharma Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Komipharm International Co Ltd, H2 2017  
Hepatocellular Carcinoma - Pipeline by Kowa Co Ltd, H2 2017  
Hepatocellular Carcinoma - Pipeline by Ligand Pharmaceuticals Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Lixte Biotechnology Holdings Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by MaxCyte Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by MedImmune LLC, H2 2017  
Hepatocellular Carcinoma - Pipeline by Medivir AB, H2 2017  
Hepatocellular Carcinoma - Pipeline by Merck & Co Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Merck KGaA, H2 2017  
Hepatocellular Carcinoma - Pipeline by Merrimack Pharmaceuticals Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Midatech Pharma Plc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Mina Therapeutics Ltd, H2 2017  
Hepatocellular Carcinoma - Pipeline by Molecular Templates Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by MTG Biotherapeutics Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by MultiCell Technologies Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by NeuroVive Pharmaceutical AB, H2 2017  
Hepatocellular Carcinoma - Pipeline by NormOxys Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Novartis AG, H2 2017  
Hepatocellular Carcinoma - Pipeline by NovaTarg Therapeutics Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Nymox Pharmaceutical Corp, H2 2017  
Hepatocellular Carcinoma - Pipeline by Omeros Corp, H2 2017  
Hepatocellular Carcinoma - Pipeline by Oncolys BioPharma Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Oneness Biotech Co Ltd, H2 2017  
Hepatocellular Carcinoma - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017  
Hepatocellular Carcinoma - Pipeline by OSE Immunotherapeutics, H2 2017  
Hepatocellular Carcinoma - Pipeline by Panacea Pharmaceuticals Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by PepVax Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Peregrine Pharmaceuticals Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Pfizer Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Pharma Mar SA, H2 2017  
Hepatocellular Carcinoma - Pipeline by PharmAbcine Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by PharmaEssentia Corp, H2 2017  
Hepatocellular Carcinoma - Pipeline by Provecs Medical GmbH (Inactive), H2 2017  
Hepatocellular Carcinoma - Pipeline by Provectus Biopharmaceuticals Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Q BioMed Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by RedHill Biopharma Ltd, H2 2017  
Hepatocellular Carcinoma - Pipeline by Regulus Therapeutics Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Samumed LLC, H2 2017  
Hepatocellular Carcinoma - Pipeline by Saronic Biotechnology Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Shenogen Pharma Group Ltd, H2 2017



Hepatocellular Carcinoma - Pipeline by Sillajen Biotherapeutics, H2 2017  
Hepatocellular Carcinoma - Pipeline by Simcere Pharmaceutical Group, H2 2017  
Hepatocellular Carcinoma - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017  
Hepatocellular Carcinoma - Pipeline by Taiwan Liposome Company Ltd, H2 2017  
Hepatocellular Carcinoma - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017  
Hepatocellular Carcinoma - Pipeline by TC BioPharm Ltd, H2 2017  
Hepatocellular Carcinoma - Pipeline by tella Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Tessa Therapeutics Pte Ltd, H2 2017  
Hepatocellular Carcinoma - Pipeline by Therapure Biopharma Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Tiziana Life Sciences Plc, H2 2017  
Hepatocellular Carcinoma - Pipeline by TRACON Pharmaceuticals Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Tumorend LLC, H2 2017  
Hepatocellular Carcinoma - Pipeline by Twoxar Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by UbiVac LLC, H2 2017  
Hepatocellular Carcinoma - Pipeline by VasGene Therapeutics Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Vaxon Biotech, H2 2017  
Hepatocellular Carcinoma - Pipeline by Verlyx Pharma Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by VG Life Sciences Inc, H2 2017  
Hepatocellular Carcinoma - Pipeline by Vicus Therapeutics LLC, H2 2017  
Hepatocellular Carcinoma - Pipeline by Xspray Pharma AB, H2 2017  
Hepatocellular Carcinoma - Pipeline by Yooyoung Pharm Co Ltd, H2 2017  
Hepatocellular Carcinoma - Pipeline by Zhejiang Conba Pharmaceutical Co Ltd, H2 2017  
Hepatocellular Carcinoma - Dormant Projects, H2 2017 1095  
Hepatocellular Carcinoma - Dormant Projects, H2 2017 (Contd.1), H2 2017 1096  
Hepatocellular Carcinoma - Dormant Projects, H2 2017 (Contd.2), H2 2017 1097  
Hepatocellular Carcinoma - Dormant Projects, H2 2017 (Contd.3), H2 2017 1098  
Hepatocellular Carcinoma - Dormant Projects, H2 2017 (Contd.4), H2 2017 1099  
Hepatocellular Carcinoma - Dormant Projects, H2 2017 (Contd.5), H2 2017 1100  
Hepatocellular Carcinoma - Dormant Projects, H2 2017 (Contd.6), H2 2017 1101  
Hepatocellular Carcinoma - Dormant Projects, H2 2017 (Contd.7), H2 2017 1102  
Hepatocellular Carcinoma - Discontinued Products, H2 2017 1103  
Hepatocellular Carcinoma - Discontinued Products, H2 2017 (Contd.1), H2 2017 1104  
Hepatocellular Carcinoma - Discontinued Products, H2 2017 (Contd.2), H2 2017 1105

## LIST OF FIGURES

Number of Products under Development for Hepatocellular Carcinoma, H2 2017  
Number of Products under Development by Companies, H2 2017  
Number of Products under Development by Universities/Institutes, H2 2017  
Number of Products by Top 10 Targets, H2 2017  
Number of Products by Stage and Top 10 Targets, H2 2017  
Number of Products by Top 10 Mechanism of Actions, H2 2017  
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017  
Number of Products by Top 10 Routes of Administration, H2 2017  
Number of Products by Stage and Top 10 Routes of Administration, H2 2017  
Number of Products by Top 10 Molecule Types, H2 2017  
Number of Products by Stage and Top 10 Molecule Types, H2 2017

## COMPANIES MENTIONED

AbbVie Inc  
Abivax SA  
ACEA Biosciences Inc  
Adaptimmune Therapeutics Plc  
Advenchen Laboratories LLC

Amgen Inc  
AndroScience Corp  
ArQule Inc  
Array BioPharma Inc  
Aslan Pharmaceuticals Pte Ltd  
AstraZeneca Plc  
AVEO Pharmaceuticals Inc  
Bayer AG  
BeiGene Ltd  
Bio-Cancer Treatment International Ltd  
Biomics Biotechnologies Co Ltd  
Bioneer Corp  
Blueprint Medicines Corp  
Boehringer Ingelheim GmbH  
Boston Biomedical Inc  
Bristol-Myers Squibb Co  
Can-Fite BioPharma Ltd  
CASI Pharmaceuticals Inc  
CBT Pharmaceuticals Inc  
CCRP Therapeutics GmbH  
Celgene Corp  
Celldex Therapeutics Inc  
Cellivory Therapeutics Inc  
Celsion Corp  
China Medical System Holdings Ltd  
Chipscreen Biosciences Ltd  
Chugai Pharmaceutical Co Ltd  
Conatus Pharmaceuticals Inc  
Curevac AG  
Delcath Systems Inc  
Double Bond Pharmaceutical International AB  
eFFECTOR Therapeutics Inc  
Eiger BioPharmaceuticals Inc  
Eisai Co Ltd  
Eli Lilly and Co  
Epeius Biotechnologies Corp  
Epizyme Inc  
eTheRNA Immunotherapies NV  
Eureka Therapeutics Inc  
Exelixis Inc  
F. Hoffmann-La Roche Ltd  
Faron Pharmaceuticals Oy  
Galaxy Biotech LLC  
Genelux Corp  
Genentech Inc  
Genoscience Pharma  
Genosco Inc  
Gilead Sciences Inc  
GlaxoSmithKline Plc  
Golden Biotechnology Corp  
Green Cross Cell Corp  
Green Cross Corp  
H3 Biomedicine Inc  
Horizon Pharma Plc  
Immatics Biotechnologies GmbH

Immunicum AB  
Immunitor Inc  
Immunomedics Inc  
Immunovative Therapies Ltd  
In-Cell-Art SAS  
Incyte Corp  
Inovio Pharmaceuticals Inc  
Inspyr Therapeutics Inc  
InteRNA Technologies BV  
Ipsen SA  
Jiangsu Hengrui Medicine Co Ltd  
Johnson & Johnson  
KAHR medical Ltd  
Karcinolys SAS  
Kite Pharma Inc  
Komipharm International Co Ltd  
Kowa Co Ltd  
Ligand Pharmaceuticals Inc  
Lixte Biotechnology Holdings Inc  
MaxCyte Inc  
MedImmune LLC  
Medivir AB  
Merck & Co Inc  
Merck KGaA  
Merrimack Pharmaceuticals Inc  
Midatech Pharma Plc  
Millennium Pharmaceuticals Inc  
Mina Therapeutics Ltd  
Molecular Templates Inc  
MTG Biotherapeutics Inc  
MultiCell Technologies Inc  
NeuroVive Pharmaceutical AB  
NormOxys Inc  
Novartis AG  
NovaTarg Therapeutics Inc  
Nymox Pharmaceutical Corp  
Omeros Corp  
Oncolys BioPharma Inc  
Oneness Biotech Co Ltd  
Ono Pharmaceutical Co Ltd  
OSE Immunotherapeutics  
Panacea Pharmaceuticals Inc  
PepVax Inc  
Peregrine Pharmaceuticals Inc  
Pfizer Inc  
Pharma Mar SA  
PharmAbcine Inc  
PharmaEssentia Corp  
Provecs Medical GmbH (Inactive)  
Provectus Biopharmaceuticals Inc  
Q BioMed Inc  
RedHill Biopharma Ltd  
Regulus Therapeutics Inc  
Samumed LLC  
Saronic Biotechnology Inc



Shenogen Pharma Group Ltd  
Sillajen Biotherapeutics  
Simcere Pharmaceutical Group  
Sun Pharma Advanced Research Company Ltd  
Taiwan Liposome Company Ltd  
Takeda Pharmaceutical Co Ltd  
TC BioPharm Ltd  
tella Inc  
Tessa Therapeutics Pte Ltd  
Therapure Biopharma Inc  
Tiziana Life Sciences Plc  
TRACON Pharmaceuticals Inc  
Tumorend LLC  
Twoxar Inc  
UbiVac LLC  
VasGene Therapeutics Inc  
Vaxon Biotech  
Verlyx Pharma Inc  
VG Life Sciences Inc  
Vicus Therapeutics LLC  
Xspray Pharma AB  
Yooyoung Pharm Co Ltd  
Zhejiang Conba Pharmaceutical Co Ltd

### I would like to order:

**Product name:** Hepatocellular Carcinoma - Pipeline Review, H2 2017  
**Product link:** <https://marketpublishers.com/r/HDDA6A0D3B4EN.html>  
**Product ID:** HDDA6A0D3B4EN  
**Price:** US\$ 2,500.00 (Single User License / Electronic Delivery)

*If you want to order Corporate License or Hard Copy, please, contact our Customer Service: [office@marketpublishers.com](mailto:office@marketpublishers.com)*

### Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/HDDA6A0D3B4EN.html>

### To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
E-mail:  
Company:  
Address:  
City:  
Zip/Post Code:  
Country:  
Tel:  
Fax:  
Your message:

\* All fields are required

Customer Signature \_\_\_\_\_

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at [https://marketpublishers.com/docs/terms\\_conditions.html](https://marketpublishers.com/docs/terms_conditions.html)

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**